How LSD1 affects small cell lung cancer and its treatment
Official title: Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer
Funded at Dana-Farber Cancer Inst · NIH-10979170 · Data updated 2026-11-12
This study is looking into how a protein called LSD1 affects small cell lung cancer, trying to find out why some tumors respond well to new treatments while others don’t, with the goal of helping doctors create better therapies for patients who need them.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 6, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $467,060 |
| NIH project number | 5R37CA269990-03 |
| Project ID | NIH-10979170 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with small cell lung cancer, particularly those whose tumors may be sensitive to LSD1 inhibitors.
✕Less likely to help
Patients with other types of lung cancer or those whose tumors are not responsive to LSD1 inhibitors may not benefit from this research.
What this research studies
This research investigates the role of the LSD1 protein in small cell lung cancer (SCLC), a type of cancer that currently lacks effective targeted therapies. The study aims to understand why some SCLC tumors respond well to LSD1 inhibitors while others do not, using advanced techniques like CRISPR/Cas9 to identify key mechanisms and potential biomarkers. By uncovering these mechanisms, the research seeks to improve treatment strategies, making LSD1 inhibitors more effective for patients who are resistant to current therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for small cell lung cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Other research has shown promising results with LSD1 inhibitors in small cell lung cancer, indicating that this approach has potential for success.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Oser, Matthew Gilbert — Dana-Farber Cancer Inst
- Study coordinator: Oser, Matthew Gilbert
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.